Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 130.23 |
| Open | 130.82 |
| Bid | 130.47 x 800 |
| Ask | 131.68 x 800 |
| Day's range | 129.95 - 130.88 |
| 52-week range | 99.14 - 133.10 |
| Volume | |
| Avg. volume | 8,207,993 |
| Market cap | 329.417B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 144.51 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (2.37%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Business Wire
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
RAHWAY, N.J., May 09, 2024--Merck Provides Update on Phase 3 KEYNOTE-B21 Trial
- Business Wire
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
RAHWAY, N.J., May 08, 2024--Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
- Business Wire
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
© 2024 Yahoo. All rights reserved.